Executive Summary Pfizer’s management of sildenafil citrate’s loss of exclusivity (LOE) in the United States is the closest thing small-molecule […]
Viagra’s Generic Cliff: Why It Wasn’t a Free-for-All Read Post »
Why Asia is the New Biosimilar Battleground The Patent Cliff Meets a Demographic Supercycle The most consequential commercial event in
Introduction: The Structural Collapse of the Primary Care Model The pharmaceutical industry is currently navigating a seismic shift, often described
1. The Core Thesis: A $58 Billion Industry Running a $400 Billion Race India’s pharmaceutical sector occupies a paradoxical position
Who this is for: Pharma and biotech IP teams, R&D leads, portfolio managers, and institutional investors tracking the $654 billion
Personalized Medicine Patent Strategy: The Complete IP Playbook for Pharma and Biotech Read Post »
A deep-dive reference for pharma IP teams, ANDA filers, litigation counsel, and institutional investors. Updated 2025. What the Orange Book
The pharmaceutical industry loves a good narrative about convergence. Drugs are meeting devices. Biologics are meeting sensors. Software is meeting
Global Key Takeaways The WHO Essential Medicines List covers more than 500 drugs that health systems are expected to keep
Optimization of Pharmaceutical R&D Portfolios: Strategic IP Valuation and Risk Mitigation in Regulated Markets Pharmaceutical R&D requires a capital allocation
Mastering Strategic Decision-Making in the Pharmaceutical R&D Portfolio Read Post »
Sign in or create a free account to read this DrugPatentWatch article
